Citation Information :
Srivastava R, Kundu A, Pradhan D, Jyoti B, Chokotiya H, Parashar P. A Comparative Study to Evaluate the Efficacy of Curcumin Lozenges (TurmNova®) and Intralesional Corticosteroids with Hyaluronidase in Management of Oral Submucous Fibrosis. J Contemp Dent Pract 2021; 22 (7):751-755.
Aim and objective: This study aims to compare the efficacy of TurmNova® lozenges and its active ingredient “curcumin” as a low-cost, safe, and noninvasive chemopreventive agent with intralesional corticosteroids (with hyaluronidase) in the management of oral submucous fibrosis (OSMF).
Materials and methods: A total of 80 patients with group III OSMF (Khanna JN and Andrade NN classification) visiting the dental outpatient clinic of the Department of Oral Medicine and Radiology Rama Dental College Hospital and Research Center, Kanpur, were selected for the study. A total of 80 patients were randomly divided into two groups (40 participants each): group A to whom TurmNova® lozenges containing turmeric extract 100 mg along with clove oil 10 mg three times daily for 3 months were given and group B to whom intralesional infiltration of 2 mL dexamethasone (4 mg/mL) + hyaluronidase 1500 IU dissolved in 0.5 mL of 2% lignocaine twice a week for 3 months was given. Data were analyzed using the IBM SPSS Statistics, version 21 (IBM Corp. Released 2012. IBM SPSS Statistics for Windows, version 21.0. Armonk, New York: IBM Corp.)
Results: Statistical analysis revealed that there was significant clinical improvement in mouth opening and subjective symptoms, like burning sensation/pain associated with the lesion and tongue protrusion in the group A as compared to group B.
Conclusion: Curcumin (100 mg) in an innovative delivery system of lozenge results in a higher level of plasma curcumin level. The aforementioned dosages prevent its biotransformation and inactivation by the liver enzymes. Because of these properties, curcumin lozenges are safer, low-cost, and effective alternative treatment in contrast to the present traditional treatment. Further long-term, prospective, large-scale studies need to be done.
Clinical significance: Curcumin has a role in the treatment of oral premalignant conditions and acts as a very effective chemopreventive agent in the prevention of cancer.
Gupta SC, Yadav YC. “MISI” an etiologic factor in oral submucous fibrosis. Indian J Otolaryngol 1978;30:5. DOI: 10.1007/BF02992043.
Murti PR, Bhonsle RB, Gupta PC, et al. Etiology of oral submucous fibrosis with special reference to the role of arecanut chewing. J Oral Pathol Med 1995;24(4):145–152. DOI: 10.1111/j.1600-0714.1995.tb01156.x.
Pindborg JJ, Sirsat SM. Oral submucous fibrosis. Oral Surg Med Oral Pathol 1966;22:764–779. DOI: 10.1016/0030-4220(66)90367-7.
Seedat HA, Van Wyk CW. Submucous fibrosis (SF) in exbetel nut chewers: a report of 14 cases. J Oral Pathol Med 1988;17:226–229. DOI: 10.1111/j.1600-0714.1988.tb01529.x.
Hebbar PB, Sheshaprasad R, Gurudath S, et al. Oral submucous fibrosis in India: are we progressing? Indian J Cancer 2014;51(3):222–226. DOI: 10.4103/0019-509X.146724.
Wollina U, Verma SB, Ali FM, et al. Oral submucous fibrosis: an update. Clin Cosmet Investig Dermatol 2015:8:193–204. DOI: 10.2147/CCID.S80576.
Hazarey VK, Sakrikar AR, Ganvir SM. Efficacy of curcumin in the treatment for oral submucous fibrosis – a randomized clinical trial. J Oral Maxillofac Pathol 2015;19(2):145–152. DOI: 10.4103/0973-029X.164524.
Srivastava A, Agarwal R, Chaturvedi TP, et al. Clinical evaluation of the role of tulsi and turmeric in the management of oral submucous fibrosis: a pilot, prospective observational study. J Ayurveda Integr Med 2015;6(1):45–49. DOI: 10.4103/0975-9476.146563.
Katzung B, Masters S, Trevor A. Basic and clinical pharmacology. 12th ed. McGraw Hill Professional Publishers; 2012.
Patil S, Sghaireen MG, Maheshwari S, et al. Comparative study of the efficacy of lycopene and aloe vera in the treatment of oral submucous fibrosis. Int J Health Allied Sci 2015;4(1):13–17. DOI: 10.4103/2278-344X.149216.
James L, Shetty A, Rishi D, et al. Management of oral submucous fibrosis with injection of hyaluronidase and dexamethasone in Grade III oral submucous fibrosis: a retrospective study. J Int Oral Health 2015;7:82–85. PMCID: PMC4588796.
Das DA, Balan A, SreeLatha KT. Comparative study of the efficacy of curcumin and turmeric oil as chemopreventive agents in oral submucous fibrosis: a clinical and histopatholgical evaluation. JIAOMR 2010;22(2):88–92. DOI: 10.5005/jp-journals-10011-1021.
Menon S, Mhatre M, Rajarshi M, et al. Bioavailability of curcumin from a novel mouth dissolving lozenge. Int J Basic Clin Pharmacol 2018;7(3):561–568. DOI: 10.18203/2319-2003.ijbcp20180674.
Reddy RC, Dany A. Staging and medical management of oral submucous fibrosis. J Sci Dent 2012;2:22–27. DOI: 10.15713/ins.jcri.18.
Rai B, Kaur J, Jacobs R, et al. Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress. J Oral Sci 2010;52(2):251–256. DOI: 10.2334/josnusd.52.251.